iSERA Lifesciences Reports Quarterly Results for June 30, 2026
iSERA Lifesciences Ltd (formerly Covidh Technologies Limited) has released its un-audited financial results for the quarter ended June 30, 2026. The results were reviewed by independent auditors and approved by the company's Board of Directors.The company, which operates exclusively in the IT/ITES business segment, presented its unaudited Statement of Profit and Loss showing key financial metrics across three periods: the current quarter (June 30, 2026), the previous quarter (March 31, 2026), and the full year ended March 31, 2026.
Financial Performance Snapshot (Rs. in Lakhs)
The financial performance details from the Unaudited Statement of Profit and Loss are summarized below:| Particulars | Quarter Ended 30-06-2026 (Unaudited) | Quarter Ended 31-03-2026 (Audited) | Year Ended 31-03-2026 (Audited) |
|---|---|---|---|
| Revenue From Operations | 11,618 | 577 | 135.50 |
| Total Revenue | 12,195 | 142.52 | - |
| Employee benefits expense | 231 | 525 | - |
| Other Expenses | 31.31 | 154 | 103.63 |
| Total Expenses | 33.62 | 5927 | 108.88 |
| Profit/Loss before Tax | (33.62) | 5,208 | 3,364 |
| Profit/Loss before Tax | (33.62) | 3.54 | 33.04 |
| Total Comprehensive Income | (33.62) | 54.98 | 25.94 |
Key Financial Highlights
Revenue and Expenses:For the quarter ended June 30, 2026, the company reported a Total Revenue of 12,195 Lakhs. The total expenses for this period amounted to 33.62 Lakhs.
Profitability:
The Statement of Profit and Loss showed the following profitability figures:
- Profit/Loss before Tax (Quarter Ended June 30, 2026): (33.62) Lakhs
- Profit/Loss before Tax (Quarter Ended March 31, 2026): 5,208 Lakhs
- Profit/Loss before Tax (Year Ended March 31, 2026): 3,364 Lakhs
The results for the quarter ended June 30, 2026, showed a Total Comprehensive Income of (33.62) Lakhs, compared to 54.98 Lakhs in the previous quarter and 25.94 Lakhs for the full year.
Earnings Per Share:
The Earnings Per Share (EPS) figures are as follows:
| Metric | Quarter Ended 30-06-2026 | Quarter Ended 31-03-2026 | Year Ended 31-03-2026 |
|---|---|---|---|
| Basic EPS | (33.62) | 158 | 0.74 |
| Diluted EPS | (33.62) | 158 | 0.74 |
Independent Auditor's Review
The results were subjected to an Independent Auditor's Review Report, conducted in accordance with Standard on Review Engagements (SRE 2410). The review confirmed that the accompanying Statement was prepared according to Indian Accounting Standards 34 (Ind AS 34) and Section 133 of the Companies Act, 2013.Stock Price Movement
At 14:31, iSERA Lifesciences Ltd's shares are ticking flat today, currently priced at the intraday level of ₹143.90. This stability is complete as the stock has been trading entirely locked between the high and low, both registering identically at ₹143.90.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.